| 狄 悦,杨一卿,齐正元,李春娇,付志强.基于血清IgE水平及嗅功能变化探究奥马珠单抗在变应性鼻炎患者中的应用价值[J].现代生物医学进展英文版,2024,(5):966-970. |
| 基于血清IgE水平及嗅功能变化探究奥马珠单抗在变应性鼻炎患者中的应用价值 |
| Application Value of Omalizumab on Patients with Allergic Rhinitis Based on Changes of Serum IgE Level and Olfactory Function |
| Received:August 04, 2023 Revised:August 23, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.05.030 |
| 中文关键词: 血清IgE 嗅功能 奥马珠单抗 变应性鼻炎 |
| 英文关键词: Serum IgE Olfactory function Omalizumab Allergic rhinitis |
| 基金项目:秦皇岛市卫生健康委员会课题（202101A114） |
|
| Hits: 338 |
| Download times: 216 |
| 中文摘要: |
| 摘要 目的：探究基于血清IgE水平及嗅功能变化探究奥马珠单抗在变应性鼻炎患者中的应用价值。方法：选取2021年1月-2022年12月期间我院就诊80例的变应性鼻炎患者，并按照单双号法随机分为观察组（应用奥马珠单抗治疗，40例）和对照组（应用常规药物治疗，40例）。比较两组患者治疗3个月后的临床疗效及治疗期间不良反应（鼻出血、口咽干、鼻腔干）；比较两组患者治疗前和治疗3个月后的免疫功能（血清IgE、CD3+、CD4+、CD8+）、鼻内镜检查结果（炎性渗出、水肿、囊泡）、嗅功能变化和生活质量[鼻结膜炎生活质量量表（RQLQ）]。结果：治疗3个月后，观察组的临床疗效显著高于对照组（P<0.05）；两组不良反应发生率比较差异无统计学意义（P>0.05）。治疗3个月后，两组的IgE、CD8+水平、鼻内镜检查结果和RQLQ评分均较治疗前显著降低，且观察组显著低于对照组（P均<0.05）；两组的CD3+、CD4+水平和嗅功能均较治疗前显著提高，且观察组显著高于对照组（P均<0.05）。结论：奥马珠单抗能够有效减轻患者的症状、改善免疫功能，同时显著提高患者的嗅功能，具有良好的安全性，对患者的生活质量有着积极的影响。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the application value of omalizumab on patients with allergic rhinitis based on changes of serum IgE level and olfactory function. Methods: 80 patients with allergic rhinitis admitted to our hospital from January 2021 to December 2022 were selected and randomly divided into observation group (omalizumab treatment, 40 cases) and control group (conventional drug treatment, 40 cases) according to the odd-even number method. The clinical efficacy after 3 months of treatment and adverse reactions (epistaxis, oropharyngeal dryness, nasal dryness) during treatment, immune function (serum IgE, CD3+, CD4+, CD8+), nasal endoscopy results (inflammatory exudation, edema, vesicles), olfactory function change and quality of life [Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)] before treatment and after 3 months of treatment were compared between the two groups. Results: The clinical efficacy in observation group was significantly higher than that in control group after 3 months of treatment (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). After 3 months of treatment, IgE, CD8+, nasal endoscopy results and RQLQ score in both groups were significantly reduced compared with those before treatment, and the above indicators in observation group were significantly lower than those in control group (all P<0.05). The levels of CD3+ and CD4+ and olfactory function in both groups were significantly higher than those before treatment, and the indicators were significantly higher in observation group (all P<0.05). Conclusion: Omalizumab can effectively relieve the symptoms, improve the immune function, and significantly enhance the olfactory function of patients, and it has good safety and has a positive impact on the quality of life of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
